Abstract
Ranibizumab, an intravitreally administered inhibitor of vascular endothelial growth factor (VEGF), is approved for the treatment of visual impairment associated with diabetic macular oedema (DME) in the EU. In four well designed, phase II or III trials (RESOLVE, RESTORE, RIDE and RISE), 1-2 years' treatment with ranibizumab was more effective than sham or focal/grid laser therapy in improving best corrected visual acuity (BCVA) and reducing central retinal thickness (CRT) in patients with visual impairment associated with DME. Additionally, in two well designed phase III trials (RESTORE and DRCR.net-1), 1 year of treatment with ranibizumab as an adjunct to laser therapy was more effective than laser monotherapy in improving BCVA and CRT in patients with visual impairment associated with DME. Improvements in BCVA with ranibizumab alone or as an adjunct to laser therapy were observed at the first follow-up visits in these studies (i.e. 1-4 weeks after the start of treatment), and were associated with gains in vision-related quality of life, as assessed using the National Eye Institute Visual Functioning Questionnaire-25. The ocular and non-ocular adverse event profile of ranibizumab in patients with DME is similar to that observ...Continue Reading
References
May 1, 1984·Survey of Ophthalmology·F L Ferris, A Patz
Oct 3, 2006·Ophthalmology·Dal W ChunJoy M Bankert
Oct 13, 2006·Retina·Napoleone FerraraRobert Kim
Oct 19, 2006·American Journal of Ophthalmology·Quan Dong NguyenPeter A Campochiaro
Jan 5, 2007·The British Journal of Ophthalmology·L L KnudsenA Gorst-Rasmussen
May 25, 2007·Drugs·Stephanie K A BlickAntona J Wagstaff
Jul 14, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·M Vaughn Emerson, Andreas K Lauer
Aug 24, 2007·Experimental Eye Research·John LoweMauricio Maia
Oct 2, 2008·Retina·David R FintakSanjay Sharma
Jan 27, 2009·Ophthalmology·Ronald KleinBarbara E K Klein
Aug 22, 2009·Retina·Giuseppe QuerquesNicola Delle Noci
Aug 25, 2009·Ophthalmology·Quan Dong NguyenUNKNOWN READ-2 Study Group
Jan 16, 2010·Eye·M S Blumenkranz
Apr 30, 2010·Ophthalmology·UNKNOWN Diabetic Retinopathy Clinical Research NetworkJennifer K Sun
May 1, 2010·Current Medical Research and Opinion·Er ChenJoan Fortuny
Jun 29, 2010·Lancet·Ning CheungTien Yin Wong
Sep 22, 2010·Ophthalmology·Quan Dong NguyenUNKNOWN READ-2 Study Group
Oct 12, 2010·Nature Medicine·Napoleone Ferrara
Oct 23, 2010·Drugs·Francesco Boscia
Oct 29, 2010·Diabetes Care·Pascale MassinSebastian Wolf
Mar 12, 2011·Retina·UNKNOWN Diabetic Retinopathy Clinical Research NetworkCynthia R Stockdale
Apr 5, 2011·Ophthalmology·Michael J ElmanUNKNOWN Diabetic Retinopathy Clinical Research Network
Apr 5, 2011·Ophthalmology·Paul MitchellUNKNOWN RESTORE study group
Oct 4, 2011·Clinical Ophthalmology·Francesco BandelloPierluigi Iacono
Citations
Oct 6, 2012·Drugs & Aging·James E Frampton
Mar 30, 2013·Drugs & Aging·James E Frampton
Aug 27, 2013·Brain Research·Guzel BikbovaShuichi Yamamoto
Jul 17, 2014·PloS One·Stephane RégnierVladimir Bezlyak
Jun 15, 2013·Clinical Interventions in Aging·Angie H C Fong, Timothy Y Y Lai
Mar 19, 2013·Clinical Ophthalmology·Christos HaritoglouMarcus Kernt
Dec 19, 2015·Expert Review of Clinical Pharmacology·Christos HaritoglouArmin Wolf
May 27, 2014·Expert Opinion on Drug Metabolism & Toxicology·Rupal Morjaria, Ngai Victor Chong
Jul 31, 2013·Ophthalmology·Michael A GrassiUNKNOWN DCCT/EDIC Research Group
Sep 21, 2013·Ophthalmic Surgery, Lasers & Imaging Retina·Ziya KapranO Murat Uyar
Jul 26, 2013·Ophthalmic Surgery, Lasers & Imaging Retina·David TelanderSeenu M Hariprasad
Sep 3, 2013·European Heart Journal·UNKNOWN Authors/Task Force MembersRobert G Xuereb
Oct 24, 2013·Expert Opinion on Investigational Drugs·Edward Faught
Nov 6, 2018·Diabetes·Karen L OnionsRebecca R Foster
Jun 11, 2019·BMJ Open Ophthalmology·Usha ChakravarthySusanne Lupton
May 28, 2013·International Journal of Oncology·Gi Dae KimSang Kook Lee
May 10, 2013·The Annals of Pharmacotherapy·Kirk E Evoy, Steven R Abel
Jan 16, 2021·Paediatric Drugs·Arnold Lee, Matt Shirley